NCT05991401View on ClinicalTrials.gov

Evaluate the Effect of Clarithromycin/Rifampicin on the Pharmacokinetics of DA-8010 in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 18, 2023

Primary Completion Date

November 6, 2023

Study Completion Date

November 17, 2023

Conditions
Healthy
Interventions
DRUG

DA-8010 5mg

\[Period 1\] DA-8010 5mg \[Period 2\] DA-8010 5mg, Clarithromycin 500mg \[Period 3\] DA-8010 5mg, Rifampicin 600mg

DRUG

Clarithromycin 500mg

\[Period 2\] DA-8010 5mg, Clarithromycin 500mg

DRUG

Rifampicin 600mg

\[Period 3\] DA-8010 5mg, Rifampicin 600mg

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Dong-A ST Co., Ltd.

INDUSTRY